EGFR and lung carcinoma: In general, previous studies based on patients with lung cancer from Xuanwei/Qujing showed that a higher proportion of EGFR compound mutations and KRAS mutations were observed, although EGFR mutation rate in patients with lung cancer patients from Xuanwei was still controversial (9–12, 24, 28, 29, 33–35) (Table 4).